Compare Gold Fields Limited (GFI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Novartis AG — how do they compare? Gold Fields Limited trades at $32.17 (market cap $29.07B), while Novartis AG trades at $152.98 (market cap $287.66B). The key difference: Novartis AG is far larger — about 9.9× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (7.03%). Which is the better fit depends on your goals.
| GFI | NVS | |
|---|---|---|
Market Cap | $29.07B | $287.66B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $168.62 |
52-Week Low | $23.95 | $113.50 |
Enterprise Value | $30.51B | $327.68B |
Dividend Yield | 7.03% | 3.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $32.28, down 3.15% today, amid a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 40.76% net income margin and 52.33% ROE, while valuation ratios like P/E of 8.37 suggest undervaluation. Recent earnings were mixed, with a Q1 2025 beat but Q2 and Q4 2025 misses, and cash flow trends improved significantly in 2025 projections. News highlights operational challenges from inflation and geopolitical factors, though long-term value arguments persist.
The outlook balances deep value against near-term headwinds. Analyst consensus leans bullish with a $52.75 price target, but technical weakness and cost pressures pose risks. Investment appeal hinges on execution of production targets and gold price stability, with high ROE supporting shareholder returns.
NVS trades at $152.51, up 1.43% today, with a bearish technical signal despite strong profitability metrics including a 75.38% gross margin and 35.21% ROE. Recent earnings show mixed results, missing Q1 2026 estimates but beating Q4 2025. The company is actively expanding its oncology pipeline through acquisitions like Myricx Bio for up to $1.5 billion (Reuters, 2026-07-06).
The outlook is balanced; robust cash flow and high margins support growth, but rising debt-to-asset ratios and cautious analyst consensus (68% hold) indicate near-term headwinds. Key risks include execution of pipeline developments and competitive pressures in pharmaceuticals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
